Compare NXPL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXPL | COCH |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | 180 | 47 |
| Industry | Telecommunications Equipment | Blank Checks |
| Sector | Telecommunications | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | NXPL | COCH |
|---|---|---|
| Price | $5.66 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 8.5K | ★ 121.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.36 |
| 52 Week High | $7.40 | $1.89 |
| Indicator | NXPL | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 57.90 |
| Support Level | $0.60 | $0.63 |
| Resistance Level | $7.19 | $0.88 |
| Average True Range (ATR) | 0.56 | 0.04 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 20.30 | 72.00 |
NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.